CEO Research Orientation, Corporate Context and Firm Innovation in the Biopharmaceutical Industry

Nino van de Wal; Christophe Boone; Victor Gilsing; Bob Walrave

doi:10.5465/AMBPP.2017.10883abstract

CEO Research Orientation, Corporate Context and Firm Innovation in the Biopharmaceutical Industry

Nino van de Wal, Christophe Boone, Victor Gilsing, Bob Walrave

Innovation Technology Entrepreneurship and Marketing

Onderzoeksoutput: Bijdrage aan congres › Abstract › Academic

Samenvatting

This study develops and tests an integrative framework that explains when and why CEOs influence firm-level innovation. Empirical evidence from 109 CEOs of 87 U.S. based biopharmaceutical firms over the period 2001-2013 reveals that research orientated CEOs–those with an ability and motivation for science and technology–increase their firm’s innovation outcomes. The results indicate that the CEO-innovation relationship strongly depends on the extent of CEO discretion, which is shaped by the corporate context. A more detailed analysis shows that research oriented CEOs influence innovation through a R&D intensive strategy. These insights contribute to a more comprehensive understanding of CEO strategic choices and processes that result in firm-level innovation, and build a better understanding of why firms differ in their innovation performance

Originele taal-2	Engels
Aantal pagina's	1
DOI's	https://doi.org/10.5465/AMBPP.2017.10883abstract
Status	Gepubliceerd - 2017
Evenement	77th Annual Meeting of the Academy of Management, AOM 2017 - Atlanta, Verenigde Staten van Amerika Duur: 4 aug. 2017 → 8 aug. 2017 Congresnummer: 77 http://aom.org/meetings/aom2017.html

Congres

Congres	77th Annual Meeting of the Academy of Management, AOM 2017
Verkorte titel	AOM 2017
Land/Regio	Verenigde Staten van Amerika
Stad	Atlanta
Periode	4/08/17 → 8/08/17
Internet adres	http://aom.org/meetings/aom2017.html

Toegang tot document

10.5465/AMBPP.2017.10883abstract

Citeer dit

@conference{7ab17fd3ead048e8995f43341a3af908,

title = "CEO Research Orientation, Corporate Context and Firm Innovation in the Biopharmaceutical Industry",

abstract = "This study develops and tests an integrative framework that explains when and why CEOs influence firm-level innovation. Empirical evidence from 109 CEOs of 87 U.S. based biopharmaceutical firms over the period 2001-2013 reveals that research orientated CEOs–those with an ability and motivation for science and technology–increase their firm{\textquoteright}s innovation outcomes. The results indicate that the CEO-innovation relationship strongly depends on the extent of CEO discretion, which is shaped by the corporate context. A more detailed analysis shows that research oriented CEOs influence innovation through a R&D intensive strategy. These insights contribute to a more comprehensive understanding of CEO strategic choices and processes that result in firm-level innovation, and build a better understanding of why firms differ in their innovation performance",

author = "{van de Wal}, Nino and Christophe Boone and Victor Gilsing and Bob Walrave",

year = "2017",

doi = "10.5465/AMBPP.2017.10883abstract",

language = "English",

note = "77th Annual Meeting of the Academy of Management, AOM 2017, AOM 2017 ; Conference date: 04-08-2017 Through 08-08-2017",

url = "http://aom.org/meetings/aom2017.html",

}

TY - CONF

T1 - CEO Research Orientation, Corporate Context and Firm Innovation in the Biopharmaceutical Industry

AU - van de Wal, Nino

AU - Boone, Christophe

AU - Gilsing, Victor

AU - Walrave, Bob

N1 - Conference code: 77

PY - 2017

Y1 - 2017

N2 - This study develops and tests an integrative framework that explains when and why CEOs influence firm-level innovation. Empirical evidence from 109 CEOs of 87 U.S. based biopharmaceutical firms over the period 2001-2013 reveals that research orientated CEOs–those with an ability and motivation for science and technology–increase their firm’s innovation outcomes. The results indicate that the CEO-innovation relationship strongly depends on the extent of CEO discretion, which is shaped by the corporate context. A more detailed analysis shows that research oriented CEOs influence innovation through a R&D intensive strategy. These insights contribute to a more comprehensive understanding of CEO strategic choices and processes that result in firm-level innovation, and build a better understanding of why firms differ in their innovation performance

AB - This study develops and tests an integrative framework that explains when and why CEOs influence firm-level innovation. Empirical evidence from 109 CEOs of 87 U.S. based biopharmaceutical firms over the period 2001-2013 reveals that research orientated CEOs–those with an ability and motivation for science and technology–increase their firm’s innovation outcomes. The results indicate that the CEO-innovation relationship strongly depends on the extent of CEO discretion, which is shaped by the corporate context. A more detailed analysis shows that research oriented CEOs influence innovation through a R&D intensive strategy. These insights contribute to a more comprehensive understanding of CEO strategic choices and processes that result in firm-level innovation, and build a better understanding of why firms differ in their innovation performance

U2 - 10.5465/AMBPP.2017.10883abstract

DO - 10.5465/AMBPP.2017.10883abstract

M3 - Abstract

T2 - 77th Annual Meeting of the Academy of Management, AOM 2017

Y2 - 4 August 2017 through 8 August 2017

ER -

CEO Research Orientation, Corporate Context and Firm Innovation in the Biopharmaceutical Industry

Samenvatting

Congres

Toegang tot document

Vingerafdruk

Citeer dit